Geode Capital Management LLC Decreases Stake in Spero Therapeutics, Inc. (NASDAQ:SPRO)

Geode Capital Management LLC reduced its position in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 2.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 481,187 shares of the company’s stock after selling 11,000 shares during the period. Geode Capital Management LLC owned 0.89% of Spero Therapeutics worth $645,000 at the end of the most recent quarter.

Separately, Acadian Asset Management LLC lifted its position in shares of Spero Therapeutics by 40.6% in the second quarter. Acadian Asset Management LLC now owns 1,071,860 shares of the company’s stock worth $1,392,000 after buying an additional 309,262 shares in the last quarter. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Evercore ISI downgraded Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price on the stock. in a research report on Friday, December 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Spero Therapeutics in a research report on Monday, December 2nd. Finally, TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th.

Spero Therapeutics Stock Down 2.0 %

Shares of NASDAQ:SPRO opened at $0.98 on Friday. Spero Therapeutics, Inc. has a 52-week low of $0.92 and a 52-week high of $1.89. The stock has a market cap of $53.43 million, a P/E ratio of 14.00 and a beta of 0.63. The business’s 50 day moving average is $1.12 and its 200 day moving average is $1.25.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.